Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ORTHOPEDIATRICS CORP (KIDS)

OrthoPediatrics investor deck shows Q3 revenue up 19% to $72.7 million

Positive Impact 2 of 5 other Written later

OrthoPediatrics filed an October 2026 investor presentation under Regulation FD for executives to use in upcoming meetings with investors and analysts. The deck reports third-quarter 2026 revenue of $72.7 million, up 19% from $61.2 million a year earlier, and a narrower net loss of $5.9 million, or $0.25 per diluted share, versus $11.8 million, or $0.50 per share. It also restates full-year 2026 revenue guidance of $270.0 million to $273.0 million.

Key points

  • Q3 2026 revenue was $72.7 million, up from $61.2 million in Q3 2025, a 19% increase.
  • Q3 2026 net loss was $5.9 million ($0.25 per diluted share), compared with a net loss of $11.8 million ($0.50 per share) in Q3 2025.
  • FY2026 guidance: revenue of $270.0 million to $273.0 million, adjusted EBITDA of about $25.0 million, and free cash flow breakeven.
  • Balance sheet as of September 30, 2026 showed cash and short-term investments of $44.9 million and debt of $98.4 million.

The filing

CompanyORTHOPEDIATRICS CORP (KIDS)
Form8-K, current report
Filed with the SECOct 27, 2026, 4:15 PM ET
Accession number0001425450-26-000092

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.